High-risk prostate cancer—classification and therapy

AJ Chang, KA Autio, M Roach III, HI Scher - Nature reviews Clinical …, 2014 - nature.com
Approximately 15% of patients with prostate cancer are diagnosed with high-risk disease.
However, the current definitions of high-risk prostate cancer include a heterogeneous group …

EAU guidelines on prostate cancer

A Heidenreich, G Aus, M Bolla, S Joniau, VB Matveev… - European urology, 2008 - Elsevier
OBJECTIVES: To present a summary of the 2007 version of the European Association of
Urology (EAU) guidelines on prostate cancer (PCa). METHODS: A literature review of the …

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III …

M Bolla, L Collette, L Blank, P Warde, JB Dubois… - The Lancet, 2002 - thelancet.com
Background We did a randomised phase III trial comparing external irradiation alone and
external irradiation combined with an analogue of luteinising-hormone releasing hormone …

A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation …

ZS Zumsteg, DE Spratt, I Pei, Z Zhang, Y Yamada… - European urology, 2013 - Elsevier
Background The management of intermediate-risk prostate cancer (PCa) is controversial, in
part due to the heterogeneous nature of patients falling within this classification. Objective …

Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial

DP Dearnaley, G Jovic, I Syndikus, V Khoo… - The lancet …, 2014 - thelancet.com
Background The aim of this trial was to compare dose-escalated conformal radiotherapy
with control-dose conformal radiotherapy in patients with localised prostate cancer …

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial

AL Zietman, ML DeSilvio, JD Slater, CJ Rossi… - Jama, 2005 - jamanetwork.com
ContextClinically localized prostate cancer is very prevalent among US men, but recurrence
after treatment with conventional radiation therapy is common. ObjectiveTo evaluate the …

70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial

V Beckendorf, S Guerif, E Le Prisé, JM Cosset… - International Journal of …, 2011 - Elsevier
PURPOSE: To perform a randomized trial comparing 70 and 80 Gy radiotherapy for prostate
cancer. PATIENTS AND METHODS: A total of 306 patients with localized prostate cancer …

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy

STH Peeters, WD Heemsbergen… - Journal of Clinical …, 2006 - ascopubs.org
Purpose To determine whether a dose of 78 Gy improves outcome compared with a
conventional dose of 68 Gy for prostate cancer patients treated with three-dimensional …

Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer

MJ Zelefsky, EJ Levin, M Hunt, Y Yamada… - International Journal of …, 2008 - Elsevier
PURPOSE: To report the incidence and predictors of treatment-related toxicity at 10 years
after three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated …

Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials

GA Viani, EJ Stefano, SL Afonso - International Journal of Radiation …, 2009 - Elsevier
PURPOSE: To determine in a meta-analysis whether the outcomes in men with localized
prostate cancer treated with high-dose radiotherapy (HDRT) are better than those in men …